Moderna, Inc. Overview
Pro stress-test →Moderna is a biotechnology company specializing in messenger RNA (mRNA) medicines and is best known for developing one of the first COVID-19 vaccines authorized for emergency use. The company's mission is to deliver the greatest possible impact to people through mRNA medicines. Moderna operates across infectious diseases, oncology, and rare genetic disorders, with a expanding global manufacturing footprint.
Strategic Profile
Pro stress-test →Moderna is well positioned for growth now that it is experiencing more stable commercial demand, with disciplined execution strengthening the company's commercial engine, pipeline advancement across diseases with high unmet need, and a manufacturing network purpose-built for mRNA. The company plans to build a large seasonal vaccine franchise for at-risk populations and invest cash generated into oncology and rare disease therapeutics, delivering up to 10% revenue growth in 2026 while reducing R&D investments and diversifying into oncology.
Competitive Landscape
Pro stress-test →Moderna competes with Pfizer, BioNTech, and Novavax in COVID-19 vaccines with ongoing legal disputes over patent infringement. In oncology, Moderna differentiates through its personalized neoantigen therapy intismeran in partnership with Merck. Competitors include traditional pharma (Merck, AstraZeneca) and emerging biotech firms focused on mRNA and cancer immunotherapy.
Industry Context
Moderna, Inc. operates in Biotechnology - mRNA Therapeutics and Vaccines.
Key facts
Founded: 2010 · Headquarters: Cambridge, US · Revenue: $1.9B (2025 pre-audited) · Market cap: $15.67B